journal article·2020-01Open access

Folate-conjugated hydrophobicity modified glycol chitosan nanoparticles for targeted delivery of methotrexate in rheumatoid arthritis

Zhongqing Wu, Kanna Xu, Jikang Min, Minchang Chen, Liping Shen, Jianxue Xu, Qi Jiang, Guohong Han, Le Pan, Haidong Li

Abstract

Background: Targeted delivery to the Rheumatoid arthritis (RA) which is characterized by destruction and degeneration of bones due to chronic inflammation is of great need. RA being a chronic autoimmune disorder might result in severe disability and morbidity. A targeted delivery system is designed to deliver methotrexate (MTX) for RA. Methods: Here, we synthesized folic acid (FA) conjugated hydrophobically modified glycol chitosan (GC) self-assembled nanoparticles (FA-GC-SA) for the targeted delivery of MTX to RA. The FA conjugation and hydrophobic modification of GC by stearic acid (SA) was confirmed by Fourier-transform infrared spectroscopy (FTIR). The FA-GC-SA was exploited for developing targeted nanoparticles encapsulating MTX by the ionic gelation method. The particles were characterized and evaluated for their targeting potential in in vitro cell culture studies. Further their in vivo efficacy in arthritis induced rats using collagen was also evaluated. Results: FTIR confirms the successful modification of GC-SA and FA-GC-SA. The FA-GC-SA-MTX of size 153 ± 9 nm were prepared with high encapsulation efficiency of MTX. The FA-GC-SA-MTX size was further confirmed by transmission electron microscopy (TEM). In vitro cell studies revealed the superior efficacy of FA-GC-SA-MTX in cell cytotoxicity. Also, significantly higher cellular uptake of FA functionalized FA-GC-SA-MTX was observed in comparison to non-functionalized GC-SA-MTX attributed to folate receptors (FRs) mediated endocytosis. In vivo results confirms the potential of FA-GC-SA-MTX which reduces reduces the pro-inflammatory cytokines, paw thickness, and arthritis score in collagen induced rats. Conclusion: The results shows that FRs targeted FA-GC-SA-MTX has superior efficacy in the treatment of RA.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Rheumatoid Arthritis Research and Therapies · Advanced Drug Delivery Systems · Spondyloarthritis Studies and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopedics, The People’s Hospital of Wuxing District (Wuxing Hospital District of Huzhou First people’s Hospital healthcare group), Huzhou, Zhejiang, China

Department of Nursing, The First People’s Hospital of Huzhou, Huzhou, Zhejiang, China

Department of Orthopedics, The First People’s Hospital of Huzhou, Huzhou, Zhejiang, China

Department of Rehabilitation, The People’s Hospital of Wuxing District (Wuxing Hospital District of Huzhou First people’s Hospital healthcare group), Huzhou, Zhejiang, China

Department of Anesthesiology, The People’s Hospital of Wuxing District (Wuxing Hospital District of Huzhou First people’s Hospital healthcare group), Huzhou, Zhejiang, China

Department of Acupuncture and Massage, The People’s Hospital of Wuxing District (Wuxing Hospital District of Huzhou First people’s Hospital healthcare group), Huzhou, Zhejiang, China

Funding

Project of Administration of traditional Chinese Medicine of Zhejiang Province of China

References (33)

Show source-provided references
1. Komatsu N · Front Immunol · 2012 · 3 · 7710.3389/fimmu.2012.00077 ↗
2. 10.1038/s41413-018-0016-910.1038/s41413-018-0016-9 ↗
3. Prasad S · Prev Med · 2012 · 54 · S2910.1016/j.ypmed.2011.11.011 ↗
4. Magyari L · World J Orthop · 2014 · 5 · 51610.5312/wjo.v5.i4.516 ↗
5. 10.1016/B978-0-12-394299-9.00002-310.1016/B978-0-12-394299-9.00002-3 ↗
6. Quan L-D · Expert Opin Ther Pat · 2008 · 18 · 72310.1517/13543776.18.7.723 ↗
7. 10.1016/j.hcl.2010.09.00210.1016/j.hcl.2010.09.002 ↗
8. 10.5312/wjo.v5.i3.28310.5312/wjo.v5.i3.283 ↗
9. 10.1177/1759720X1140863510.1177/1759720X11408635 ↗
10. 10.1038/s41413-018-0016-910.1038/s41413-018-0016-9 ↗
11. 10.3390/ijms1910326410.3390/ijms19103264 ↗
12. Dwivedi P · Mater Sci Eng: C · 2019 · 102 · 11310.1016/j.msec.2019.03.009 ↗
13. Salter DN · Biochem J · 1981 · 193 · 46910.1042/bj1930469 ↗
14. Turk MJ · Arthritis Rheum · 2002 · 46 · 194710.1002/art.10405 ↗
15. 10.1186/s13075-015-0668-410.1186/s13075-015-0668-4 ↗
16. 10.1002/art.2129510.1002/art.21295 ↗
17. 10.1042/bj291085510.1042/bj2910855 ↗
18. Du Y-Z · Int J Nanomed · 2011 · 6 · 155910.2147/IJN.S23828 ↗
19. 10.1111/j.1476-5381.1963.tb01508.x10.1111/j.1476-5381.1963.tb01508.x ↗
20. Fatima N · PLoS One · 2016 · 11 · e016154810.1371/journal.pone.0161548 ↗
21. Sharma M · RSC Adv · 2016 · 6 · 2513710.1039/C5RA17599B ↗
22. Miranda MA · Colloids Surf., B · 2020 · 192 · 11110610.1016/j.colsurfb.2020.111106 ↗
23. Charles P · J Immunol (Baltimore, Md : 1950) · 1999 · 163 · 152110.4049/jimmunol.163.3.1521 ↗
24. 10.1007/s00011-017-1116-510.1007/s00011-017-1116-5 ↗
25. Rein P · Rheumatol Ther · 2017 · 4 · 24710.1007/s40744-017-0073-3 ↗
26. Min KH · J Controlled Release · 2008 · 127 · 20810.1016/j.jconrel.2008.01.013 ↗
27. Khatik R · RSC Adv · 2015 · 5 · 1650710.1039/C4RA15114C ↗
28. 10.1039/C9CC09131A10.1039/C9CC09131A ↗
29. Fearon U · Clin Exp Immunol · 2019 · 197 · 17010.1111/cei.13228 ↗
30. 10.1016/0142-9612(96)85907-210.1016/0142-9612(96)85907-2 ↗
31. 10.1186/s12951-018-0392-810.1186/s12951-018-0392-8 ↗
32. 10.1007/s13346-018-0589-210.1007/s13346-018-0589-2 ↗
33. Roger E · Mol Pharm · 2012 · 9 · 210310.1021/mp2005388 ↗